Emerging Healthcare Solutions seeks business opportunities with new, patented T-Guide Platelet Function Analyzer

Emerging Healthcare Solutions, Inc. (Pink Sheets: EHSI) under their exclusive option agreement with Thrombovision, has begun due diligence to aggressively seek the establishment of business opportunities with the new patented T-Guide Platelet Function Analyzer.

The new analyzer consists of a desktop instrument and a disposable test kit that can be located at doctors' offices and will become a front-line technology that could help prevent heart attacks, strokes and stent occlusions by directly analyzing a patient’s platelet status on-site. This new technology should enable doctors to directly measure platelet status as easily as measuring cholesterol.

“We are pursuing the due diligence with Thrombovision at a deliberate, but professional cadence and fully expect to be complete within our 90-day estimate”

In the US, cardiologists and primary care physicians manage 80 million cardiovascular visits each year, with over 30 million of these patients on Aspirin or Plavix platelet therapy. Six million new prescriptions for anti-platelet therapy are written in the US each year. T-Guide has been developed and patented to be an accurate, laser measured analysis that is reliable and economical. The test does not require any direct blood handling or exposure to blood borne illnesses. Thrombovision’s President, Dr. Edward Teitel, has expressed his excitement about the opportunity to work with Emerging Healthcare Solutions to bring this important medical technology to cardiac patients.

“We are pursuing the due diligence with Thrombovision at a deliberate, but professional cadence and fully expect to be complete within our 90-day estimate,” said Steven Price, Emerging Healthcare’s Senior Vice President for Business Development.

Congress is expected to pass a trillion-dollar healthcare measure in the short term. Some of the largest players in the industry are Pfizer, Inc. (NYSE: PFE), Eli Lilly & Co. (NYSE: LLY), Medtronic (NYSE: MDT) and Haemonetics (NYSE: HAE). All are expected to see expanded revenue under the national health plan currently working through Congress.